Cipla
Adalimumab Immunology & rheumatology
Originator: Humira · AbbVie (originally developed and marketed by Abbott Laboratories; initial U.S. approval 2002)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Plamumab | 40 mg injection | — | — | — | — |
Baricitinib Immunology & rheumatology
Originator: Olumiant · Eli Lilly and Company (co-developed with Incyte; initial U.S. approval 2018)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Barijak | 4 mg tablet (and other marketed strengths) | — | — | — | — |
Canagliflozin Diabetes & metabolic
Originator: Invokana · Janssen Pharmaceuticals (Johnson & Johnson), licensed from Mitsubishi Tanabe Pharma
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| — | — | — | — |
Dapagliflozin Diabetes & metabolic
Originator: Forxiga · AstraZeneca (originally developed with Bristol-Myers Squibb)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| — | — | — | — |
Empagliflozin Diabetes & metabolic
Originator: Jardiance · Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| — | — | — | — |
Linagliptin Diabetes & metabolic
Originator: Tradjenta · Boehringer Ingelheim (marketed in the US by Boehringer Ingelheim Pharmaceuticals, Inc.; co-promoted with Eli Lilly in several markets)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Linacip | 5 mg tablet (strip of 15) | — | — | — | — |
Sitagliptin Diabetes & metabolic
Originator: Januvia · Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc.
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Sitacip (50 mg, 100 mg); also Increglip M combos | 50 mg and 100 mg tablets | — | — | — | — |
Sofosbuvir/Velpatasvir Antivirals (hepatitis C)
Originator: Epclusa · Gilead Sciences (Gilead Sciences Ireland UC for the EU)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Hepcvel | 400 mg + 100 mg tablet | — | — | — | — |
Tofacitinib Immunology & rheumatology
Originator: Xeljanz / Xeljanz XR · Pfizer (initial U.S. approval 2012)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Tofajak | 5 mg tablet | — | — | — | — |
Vildagliptin Diabetes & metabolic
Originator: Galvus · Novartis
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Vysov and Vysov M (vildagliptin + metformin); Cipvildin and Cipvildin-M in Cipla's generic product list | Vysov 50 mg; Cipvildin-M 50 mg/1000 mg tablets | — | — | — | — |
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.